CFO
ADCT icon

Callan Family Office’s ADC Therapeutics ADCT Stock Holding History

Callan Family Office’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Sell
10,086
-2,787
-22% -$8.13K ﹤0.01% 1223
2026
Q1 		$48.3K Sell
12,873
-10,969
-46% -$43.2K ﹤0.01% 1111
2025
Q4 		$84.2K Buy
+23,842
New +$96.7K ﹤0.01% 1082

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Callan Family Office's ADCT Position: Q2 2026 in Review

Callan Family Office reduced its ADC Therapeutics (ADCT) stake by 22% in Q2 2026, selling an estimated $8.13K and leaving 10,086 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1223.

Callan Family Office first reported a position in ADCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $84.2K in Q4 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Callan Family Office held 10,086 shares of ADC Therapeutics worth $10.8K as of Q2 2026.
  • Callan Family Office sold 2,787 ADC Therapeutics shares in Q2 2026, an estimated $8.13K.
  • ADC Therapeutics made up ﹤0.01% of Callan Family Office's portfolio in Q2 2026, its #1223 holding.
  • Callan Family Office first reported a position in ADC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Callan Family Office's ADC Therapeutics position peaked at $84.2K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.